CLINICAL ROLE -
Identifying the Genomic Landscape of CDK4/6i Resistance in Patients with HR+/HER2- Metastatic Breast Cancer
Investigators have established a genomic outline of the CDK4/6i resistance in patients with breast cancer, growing the potential for novel treatments to circumvent that resistance.
Specific Education, Training Needs Required for Appropriate Therapeutic Decision-Making for Women with HR-Positive, HER2-Negative Breast Cancer
Cyclin-dependent kinase 4/6 inhibitors offer the potential to significantly improve outcomes for women with HR-positive, HER2-negative breast cancer.
Addition of Tucatinib with First-Line HER2-Positive Therapy Shows Improved Progression-Free, Overall Survival Rates
The study results also show improved outcomes for patients with brain metastases.
Study: CDK4/6 Mechanisms of Resistance Differ By Type of Inhibitor Used
Although CDK4/6 inhibitors prolong progression-free survival for patients with estrogen receptor-positive breast cancer, the ideal treatment for each patient is currently unclear until adverse effects appear.
Understanding Different Mechanisms of Resistance to Abemaciclib, Palbociclib Presents New Therapeutic Strategies
The research presented at the 2019 San Antonio Breast Cancer Symposium suggests that the different mechanisms could be exploited to overcome CDK4/6 inhibitor resistance in breast cancer patients.
Endocrine Therapy for HER-Positive, HER2-Negative Breast Cancer is Improving, but More Research Needed
Researchers say several key questions remain in the treatment of breast cancer: whether CDK4/6i therapy should be continued beyond progression, what the mechanisms of resistance are, and how agents should be selected.
The Emerging Role of Immunotherapy in Breast Cancer
"I think immunotherapy has certainly arrived for breast cancer," said Rita Nanda, MD.
When to Discuss Clinical Trials with Patients
Patricia Spears discusses what clinical trials can offer and when to start discussing them with patients. This video was filmed December 11 at the 2019 San Antonio Breast Cancer Symposium.
Five Key Studies at the San Antonio Breast Cancer Symposium 2019 Conference
Check the Pharmacy Times® website for more information and be sure to watch for daily newsletters, online conference articles and videos, and social media updates.
Stay Tuned for Upcoming Coverage of the 2019 San Antonio Breast Cancer Symposium
Specialty Pharmacy Times will be on-site in San Antonio, TX, for the 2019 San Antonio Breast Cancer Symposium, taking place December 10 to 14, 2019.